Imperial College London
Portrait Picture

ProfessorNicholasMazarakis

Faculty of Medicine, Department of Brain Sciences

Chair MolBioMedicine and Head of Gene Therapy
 
 
 
//

Contact

 

+44 (0)20 7594 7024n.mazarakis Website

 
 
//

Assistant

 

Mrs Hadeel Abdeen +44 (0)20 7594 7014

 
//

Location

 

E402Burlington DanesHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Eleftheriadou:2015:10.1002/acn3.335,
author = {Eleftheriadou, I and Manolaras, I and Irvine, E and Mazarakis, ND},
doi = {10.1002/acn3.335},
journal = {Human Gene Therapy},
pages = {A14--A15},
title = {Neuroprotection in an ALS mouse model following peripheral delivery of motor neuron targeted aCAR-IGF-1 Lentiviral vector},
url = {http://dx.doi.org/10.1002/acn3.335},
volume = {26},
year = {2015}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - ObjectiveWe have previously described the generation of coxsackievirus and adenovirus receptor (αCAR)-targeted vector, and shown that intramuscular delivery in mouse leg muscles resulted in specific retrograde transduction of lumbar-motor neurons (MNs). Here, we utilized the αCAR-targeted vector to investigate the in vivo neuroprotective effects of lentivirally expressed IGF-1 for inducing neuronal survival and ameliorating the neuropathology and behavioral phenotypes of the SOD1G93A mouse model of ALS.MethodsWe produced cell factories of IGF-1 expressing lentiviral vectors (LVs) bearing αCAR or Vesicular Stomatitis Virus glycoprotein (VSV-G) on their surface so as to compare neuroprotection from MN transduced versus muscle transduced cells. We performed intramuscular delivery of either αCAR IGF-1 or VSVG IGF-1 LVs into key muscles of SOD1G93A mice prior to disease onset at day 28. Motor performance, coordination and gait analysis were assessed weekly.ResultsWe observed substantial therapeutic efficacy only with the αCAR IGF-1 LV pretreatment with up to 50% extension of survival compared to controls. αCAR IGF-1 LV-treated animals retained muscle tone and had better motor performance during their prolonged survival. Histological analysis of spinal cord samples at end-stage further confirmed that αCAR IGF-1 LV treatment delays disease onset by increasing MN survival compared with age-matched controls. Intrastriatal injection of αCAR eGFP LV in rats leads to transduction of neurons and glia locally and neurons in olfactory bulb distally.InterpretationOur data are indicative of the efficacy of the αCAR IGF-1 LV in this model and support its candidacy for early noninvasive neuroprotective therapy in ALS.
AU  - Eleftheriadou,I
AU  - Manolaras,I
AU  - Irvine,E
AU  - Mazarakis,ND
DO  - 10.1002/acn3.335
EP  - 15
PY  - 2015///
SN  - 1043-0342
SP  - 14
TI  - Neuroprotection in an ALS mouse model following peripheral delivery of motor neuron targeted aCAR-IGF-1 Lentiviral vector
T2  - Human Gene Therapy
UR  - http://dx.doi.org/10.1002/acn3.335
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000363878700040&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/42577
VL  - 26
ER  -
Download